Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (32)
Michael A. Nauck & Timo D. Müller. (2023) Incretin hormones and type 2 diabetes. Diabetologia.
Crossref
Crossref
Simon Veedfald, Louise Vedtofte, Kirsa Skov-Jeppesen, Carolyn F Deacon, Bolette Hartmann, Tina Vilsbøll, Filip K Knop, Mikkel B Christensen & Jens J Holst. (2020) Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. The Journal of Clinical Endocrinology & Metabolism 105:3, pages e502-e510.
Crossref
Crossref
Michael A. Nauck. (2020) The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. Metabolism 103, pages 154031.
Crossref
Crossref
Michael A. Nauck & Juris J. Meier. (2018) Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism 20, pages 5-21.
Crossref
Crossref
Dana K. Andersen. 2017. Pancreatitis. Pancreatitis
211
224
.
Sara Chowdhury, Songyan Wang, Judit Dunai, Rachel Kilpatrick, Lauren Z. Oestricker, Michael J. Wallendorf, Bruce W. Patterson, Dominic N. Reeds & Burton M. Wice. (2016) Hormonal Responses to Cholinergic Input Are Different in Humans with and without Type 2 Diabetes Mellitus. PLOS ONE 11:6, pages e0156852.
Crossref
Crossref
Munenori Hiromura, Yusaku Mori, Kyoko Kohashi, Michishige Terasaki, Kyoko Shinmura, Takaharu Negoro, Hikaru Kawashima, Mao Kogure, Toshimi Wachi, Rena Watanabe, Kengo Sato, Hideki Kushima, Masako Tomoyasu, Yasuko Nakano, Yuichiro Yamada, Takuya Watanabe & Tsutomu Hirano. (2016) Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models. Circulation Journal 80:9, pages 1988-1997.
Crossref
Crossref
T. Wu, L. G. Trahair, M. J. Bound, C. F. Deacon, M. Horowitz, C. K. Rayner & K. L. Jones. (2015) Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with Type 2 diabetes: a potential role for glucose-dependent insulinotropic polypeptide?. Diabetic Medicine 32:5, pages 595-600.
Crossref
Crossref
Tongzhi Wu, Christopher K. Rayner & Michael Horowitz. 2016. Metabolic Control. Metabolic Control
137
171
.
Chee W. Chia, Juliana O. Odetunde, Wook Kim, Olga D. Carlson, Luigi Ferrucci & Josephine M. Egan. (2014) GIP Contributes to Islet Trihormonal Abnormalities in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism 99:7, pages 2477-2485.
Crossref
Crossref
Sara Chowdhury, Songyan Wang, Bruce W. Patterson, Dominic N. Reeds & Burton M. Wice. (2013) The combination of GIP plus xenin-25 indirectly increases pancreatic polypeptide release in humans with and without type 2 diabetes mellitus. Regulatory Peptides 187, pages 42-50.
Crossref
Crossref
Juris J. MeierMichael A. Nauck. (2010) Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?. Diabetes 59:5, pages 1117-1125.
Crossref
Crossref
Brock E. Schroeder & Orville Kolterman. 2010. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
57
74
.
Juris J. Meier. (2009) The contribution of incretin hormones to the pathogenesis of type 2 diabetes. Best Practice & Research Clinical Endocrinology & Metabolism 23:4, pages 433-441.
Crossref
Crossref
Christopher H.S. McIntosh, Scott Widenmaier & Su‐Jin Kim. 2009. Insulin and IGFs. Insulin and IGFs
409
471
.
Michael A. Nauck & Juris J. Meier. 2008. Pancreatic Beta Cell in Health and Disease. Pancreatic Beta Cell in Health and Disease
335
378
.
Michael A. Nauck, Wolfgang E. Schmidt & Juris J. Meier. 2007. Pharmacotherapy of Diabetes: New Developments. Pharmacotherapy of Diabetes: New Developments
111
141
.
O Andersen, SB Haugaard, JJ Holst, CF Deacon, J Iversen, UB Andersen, JO Nielsen & S Madsbad. (2005) Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy. HIV Medicine 6:2, pages 91-98.
Crossref
Crossref
Juris J. Meier, Baptist Gallwitz, Bartholomaeus Kask, Carolyn F. Deacon, Jens J. Holst, Wolfgang E. Schmidt & Michael A. Nauck. (2004) Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects. Diabetes 53:suppl_3, pages S220-S224.
Crossref
Crossref
Michael A. Nauck, Birgit Baller & Juris J. Meier. (2004) Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes. Diabetes 53:suppl_3, pages S190-S196.
Crossref
Crossref
Juris J. Meier & Michael A. Nauck. (2004) Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. Best Practice & Research Clinical Endocrinology & Metabolism 18:4, pages 587-606.
Crossref
Crossref
Michael A. Nauck, Andrea El-Ouaghlidi, Bartholomäus Gabrys, Katrin Hücking, Jens J. Holst, Carolyn F. Deacon, Baptist Gallwitz, Wolfgang E. Schmidt & Juris J. Meier. (2004) Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regulatory Peptides 122:3, pages 209-217.
Crossref
Crossref
Juris J Meier, Michael A Nauck, Nina Siepmann, Michael Greulich, Jens J Holst, Carolyn F Deacon, Wolfgang E Schmidt & Baptist Gallwitz. (2003) Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism 52:12, pages 1579-1585.
Crossref
Crossref
Juris J. Meier, Baptist Gallwitz & Michael A. Nauck. (2003) Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide. BioDrugs 17:2, pages 93-102.
Crossref
Crossref
Juris J Meier, Michael A Nauck, Wolfgang E Schmidt & Baptist Gallwitz. (2002) Gastric Inhibitory Polypeptide: the neglected incretin revisited. Regulatory Peptides 107:1-3, pages 1-13.
Crossref
Crossref
Simon A. Hinke, Richard W. Gelling, Raymond A. Pederson, Susanne Manhart, Cuilan Nian, Hans-Ulrich Demuth & Christopher H.S. McIntosh. (2002)
Dipeptidyl Peptidase IV-Resistant [
d
-Ala2]Glucose-Dependent Insulinotropic Polypeptide (GIP) Improves Glucose Tolerance in Normal and Obese Diabetic Rats
. Diabetes 51:3, pages 652-661.
Crossref
Crossref
Werner Creutzfeldt & Michael Nauck. (2009) Gut hormones and diabetes mellitus. Diabetes/Metabolism Reviews 8:2, pages 149-177.
Crossref
Crossref
L. R. RoustM. StesinV. L. GoP. C. O'BrienR. A. RizzaF. J. Service. (1988) Role of gastric inhibitory polypeptide in postprandial hyperinsulinemia of obesity. American Journal of Physiology-Endocrinology and Metabolism 254:6, pages E767-E774.
Crossref
Crossref
W. Creutzfeldt & R. Ebert. 1988. Gastrointestinal Hormones. Gastrointestinal Hormones
333
367
.
I. R. Jones, D. R. Owens, A. J. Moody, S. D. Luzio, T. Morris & T. M. Hayes. (1987) The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 30:9, pages 707-712.
Crossref
Crossref
Thure Krarup, Nina Saurbrey, Alister J. Moody, Claus Kühl & Sten Madsbad. (1987) Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus. Metabolism 36:7, pages 677-682.
Crossref
Crossref
R. Ebert & W. Creutzfeldt. (2009) Gastrointestinal peptides and insulin secretion. Diabetes/Metabolism Reviews 3:1, pages 1-26.
Crossref
Crossref